Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor κB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women

Menopause

Volumn 15, Issue 2, 2008, Pages 357-362

  Kim, Jung Gu ^a,b   Kim, Jung Hwa ^a   Lee, Dong Ock ^a   Kim, Hoon ^a   Kim, Ja Yeon ^a   Suh, Chang Suk ^a   Kim, Seok Hyun ^a,b   Choi, Young Min ^a,b  

^a Seoul National University   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

Bone mass; Estrogen plus progestogen therapy; Osteoprotegerin; Postmenopausal women; Receptor activator for nuclear factor B ligand (RANKL)

Indexed keywords

CALCITONIN; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; ESTROGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCALCIN; OSTEOPROTEGERIN; PARATHYROID HORMONE; PHOSPHORUS; PROGESTERONE;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MASS; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS;

AGED; BONE DENSITY; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; OSTEOPROTEGERIN; POSTMENOPAUSE; RANK LIGAND;

EID: 40449087995     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e318133a153     Document Type: Article

References (26)

1. Osteoporosis prevention, diagnosis, and therapy. NIH Consens Statement 2000;17:1-45.
2. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000;15:2-12.
3. Jones DH, Kong YY, Penninger JM. Role of RANKL and RANK in bone loss and arthritis. Ann Rheum Dis 2002;61(Suppl 2):32-39.
4. Rogers A, Eastell R. Circulating osteoprotegerin and receptor activator for nuclear factor κB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 2005;90:6323-6331.
5. Yano K, Tsuda E, Washida N, et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 1999;14:518-527.
6. Khosla S, Arrighi HM, Melton LJ III, et al. Correlates of osteoprotegerin levels in women and men. Osteoporos Int 2002;13:394-399.
7. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001;86:631-637.
8. Indridason OS, Franzon L, Sigurdsson G. Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. Osteoporos Int 2005;16:417-423.
9. Kudlacek S, Schneider B, Woloszczuk W, Pietschmann P, Willvonseder R. Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone 2003;32:681-686.
10. Liu JM, Zhao HY, Ning G, et al. Relationship between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20-75. Calcif Tissue Int 2005;76:1-6.
11. Pines A, Sturdee DW, Birkhauser MH, Schneider HP, Gambacciani M, Panay N. IMS updated recommendations on postmenopausal hormone therapy. Climacteric 2007;10:181-194.
12. Han KO, Choi JT, Choi HA, et al. The changes in circulating oesteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone. Clin Endocrinol 2005;62:349-353.
13. DiCarlo C, Tommaselli GA, Gargano V, et al. Effects of estrogen-progestin therapy on serum levels of RANKL, osteoprotegerin, osteocalcin, leptin, and ghrelin in postmenopausal women. Menopause 2007;14:38-44.
14. Hofbauer LC, Schoppet M, Schuller P, Viereck V, Christ M. Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women. Clin Endocrinol 2004;60:214-219.
15. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003;111:1221-1230.
16. Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev NI. The diagnosis of osteoporosis. J Bone Miner Res 1994;9:1137-1141.
17. Pulsatelli L, Dolzani P, Silvestri T, et al. Soluble receptor activator of nuclear factor-κB ligand (sRANKL)/osteoprotegerin balance in ageing and age-associated diseases. Biogerontology 2004;5:119-127.
18. Trofimov S, Pantsulaia I, Kobyliansky E, Livshits G. Circulating levels of receptor activator of nuclear factor-κB ligand/osteoprotegerin/ macrophage-colony stimulating factor in a presumably healthy human population. Eur J Endocrinol 2004;150:305-311.
19. Fahrleitner A, Prenner G, Leb G, et al. Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation. Bone 2003;32:96-106.
20. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 1999;140:4367-4370.
21. Saika M, Inoue D, Kido S, Matsumoto T. 17β-Estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-α. Endocrinology 2001;142:2205-2212.
22. Liao EY, Luo XH, Su X. Comparison of the effects of 17β-E2 and progesterone on the expression of osteoprotegerin in normal human osteoblast-like cells. J Endocrinol Invest 2002;25:785-790.
23. Rogers A, Saleh G, Hannon RA, Greenfield D, Eastell R. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J Clin Endocrinol Metab 2002;87:4470-4475.
24. Lee S, Lorenzo JA. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 1999;140:3552-3561.
25. Locklin RM, Khosla S, Turner R, Riggs BL. Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. J Cell Biochem 2003;89:180-190.
26. Prestwood KM, Pilneam CC, Burleson JA, et al. The short-term effects of conjugated estrogen on bone turnover in older women. J Clin Endocrinol Metab 1994;79:366-371.